In third pharma deal, IFM partners cGAS-STING unit with Novartis

IFM Therapeutics' subsidiary model continues to pay off as the innate immune company scores its third high-value pharma deal in as many years. The biotech teamed up with Novartis Thursday in a collaboration and acquisition option agreement for its IFM Due subsidiary less than seven months after its launch.

Novartis AG (NYSE:NVS; SIX:NOVN) will finance IFM Due's R&D costs in exchange for an option

Read the full 630 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers